INS and type 2 diabetes mellitus: In randomized controlled trials in patients with T2D, the second‐generation basal insulin analogue (BIA), insulin glargine 300 U/mL (Gla‐300), has been compared with the first‐generation BIA, insulin glargine 100 units/mL (Gla‐100), and has been shown to provide comparable glycaemic control while reducing the risk of some hypoglycaemic endpoints.5, 6, 7, 8, 9